Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DCE-MRI-Informed Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer
NCT07705919Phase 2Recruiting
- Sponsor
- The Ohio State University Comprehensive Cancer Center – James Cancer Hospital
- Start
- Oct 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial, sponsored by The Ohio State University Comprehensive Cancer Center – James Cancer Hospital. Primary endpoint: R0 resection rate. Started Oct 2026; status: recruiting.
Beyond the preview
Go deeper on NCT07705919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07705919.